Vaccine patents: a bitter pill for drug companies

The US has suggested waiving drug companies’ vaccine patents to hasten the defeat of Covid-19, sending their share prices down.

Shares in pharmaceutical companies slumped last week after the US government “threw its weight behind global plans for a patent waiver on Covid-19 vaccines to boost their production and distribution around the world”, says Julia Kollewe in The Guardian. Vaccine makers Moderna and Novavax fell by over 10%. In Hong Kong CanSino Biologics slumped by 22% and Fosun Pharma, which distributes the Pfizer/BioNTech vaccine, lost 18%.

No wonder investors “shuddered”, says The Economist. Drug companies have hitherto banked on big profits from a vaccine, with Pfizer forecasting “vaccine revenues of $26bn in 2021, with profits around $7bn”. But much of this would disappear if their know-how could be “pilfered with impunity”. Worse, “botched imitations” by generic manufacturers could “fuel vaccine hesitancy” and lead to litigation. But these arguments are unlikely to impress countries pushing for a waiver. They insist that “a pandemic is not the time to be thinking about profits”.

An unfortunate precedent

It’s not just lost profits from Covid-19 drugs keeping drug firms up at night, says the Financial Times. For decades, the US has “fiercely” protected domestic companies’ intellectual property rights in trade disputes, even to the extent of preventing cash-strapped countries trying to lower the costs of expensive HIV treatments in the late 1990s. The biotech sector fears that President Biden is now opening a “crack in the wall” that could be used to set a precedent to “make it easier to suspend patents in the future”, thus reducing the incentive for future innovation.

Investors shouldn’t panic just yet, since the US announcement is more a “symbolic milestone than a turning point”, says life-sciences news site Stat. Due to opposition from Germany and other countries it will take “months of international infighting” before any proposal is agreed at the World Trade Organisation, with the most likely outcome a “narrow” compromise involving the compulsory licensing of vaccines. What’s more, even if patents were waived today, generic manufacturers would struggle to find the “skilled expertise” required for making the vaccines. Note that even though Moderna has already opened the door to copycats, it’s unclear whether any company has tried to emulate its vaccine.

While an immediate patent waiver may be a bad idea, there are several ways in which drug and other companies could help speed up distribution in poorer countries, says The Wall Street Journal. For example, the US could make “hundreds of millions” of surplus doses in its stockpile available to countries such as India and Brazil. Countries that produce “quality vaccines” could also invest in a “major expansion” of manufacturing facilities aimed at increasing exports to poorer countries. Finally, pharma groups should speed up efforts to build up manufacturing capacity in poorer countries.

Recommended

Cryptocurrency roundup: authorities tighten the screw
Bitcoin & crypto

Cryptocurrency roundup: authorities tighten the screw

Saloni Sardana looks at the cryptocurrency stories that caught our eye this week.
21 Jan 2022
Stockmarket crash: is the “superbubble” heading for a “superbust”?
Stockmarkets

Stockmarket crash: is the “superbubble” heading for a “superbust”?

America's Nasdaq stock index is down by more than 10% after soaring to all-time highs in a "superbubble". Are we about to see a "superbust" stockmarke…
21 Jan 2022
Inflation: now we really have something to worry about
Inflation

Inflation: now we really have something to worry about

We’ve been worrying about a sharp rise in inflation for years, says Merryn Somerset Webb – now, we finally have something to worry about.
21 Jan 2022
Share tips of the week – 21 January
Share tips

Share tips of the week – 21 January

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
21 Jan 2022

Most Popular

Ask for a pay rise – everyone else is
Inflation

Ask for a pay rise – everyone else is

As inflation bites and the labour market remains tight, many of the nation's employees are asking for a pay rise. Merryn Somerset Webb explains why yo…
17 Jan 2022
Temple Bar’s Ian Lance and Nick Purves: the essence of value investing
Investment strategy

Temple Bar’s Ian Lance and Nick Purves: the essence of value investing

Ian Lance and Nick Purves of the Temple Bar investment trust explain the essence of “value investing” – buying something for less than its intrinsic v…
14 Jan 2022
US inflation is at its highest since 1982. Why aren’t markets panicking?
Inflation

US inflation is at its highest since 1982. Why aren’t markets panicking?

US inflation is at 7% – the last time it was this high interest rates were at 14%. But instead of panicking, markets just shrugged. John Stepek explai…
13 Jan 2022